The Espinosa Neuroscience Institute - Dr. Patricio Espinosa MD MPH FAAN

The Espinosa Neuroscience Institute is conducting a Clinical Trial with Aducanumab the first therapy FDA approved to demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer’s disease, from the brain is reasonably likely to reduce cognitive and functional decline in people living with Mild Cognitive Impairment early Alzheimer’s Disease. Please contact us for more information.